Cargando…

Crisaborole Inhibits Itch and Pain by Preventing Neutrophil Infiltration in a Mouse Model of Atopic Dermatitis

Crisaborole, a phosphodiesterase 4 (PDE4) inhibitor, has been approved for the treatment of mild to moderate atopic dermatitis. Atopic dermatitis is often associated with increased pain. Using a mouse model, this study investigated whether crisaborole suppresses pain associated with atopic dermatiti...

Descripción completa

Detalles Bibliográficos
Autores principales:	PAVLENKO, Darya, SEVEN, Zeynep Todurga, BYSTROM, Lauren, MARKAN, Anika, VERPILE, Rebecca, ISHIDA, Hirotake, AKIYAMA, Tasuku
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medical Journals Sweden, on behalf of the Society for Publication of Acta Dermato-Venereologica 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10461178/ https://www.ncbi.nlm.nih.gov/pubmed/37605895 http://dx.doi.org/10.2340/actadv.v103.13382

Ejemplares similares

Crisaborole for atopic dermatitis
Publicado: (2019)

Impact of Crisaborole on Sleep Outcomes in Pediatric Patients with Mild-to-Moderate Atopic Dermatitis
por: Fowler, Joseph, et al.
Publicado: (2023)

Crisaborole Ointment Improves Quality of Life of Patients with Mild to Moderate Atopic Dermatitis and Their Families
por: Simpson, Eric L., et al.
Publicado: (2018)

Neutrophils promote CXCR3-dependent itch in the development of atopic dermatitis
por: Walsh, Carolyn M, et al.
Publicado: (2019)

Subgroup Analysis of Crisaborole for Mild-to-Moderate Atopic Dermatitis in Children Aged 2 to < 18 Years
por: Luger, Thomas A., et al.
Publicado: (2022)

How to measure itch in atopic dermatitis?
por: Oosterhaven, J.A.F.
Publicado: (2020)

Itch in Atopic Dermatitis – What Is New?
por: Legat, Franz J.
Publicado: (2021)

Improvement in disease severity and pruritus outcomes with crisaborole ointment, 2%, by baseline atopic dermatitis severity in children and adolescents with mild‐to‐moderate atopic dermatitis
por: Eichenfield, Lawrence F., et al.
Publicado: (2020)

Translating the Investigator’s Static Global Assessment to the Eczema Area and Severity Index in Studies of Crisaborole for Atopic Dermatitis
por: Thyssen, Jacob P., et al.
Publicado: (2021)

Evaluating the Efficacy of Crisaborole Using the Atopic Dermatitis Severity Index and Percentage of Affected Body Surface Area
por: SILVERBERG, Jonathan I., et al.
Publicado: (2020)

Neuroimmune interactions in chronic itch of atopic dermatitis
por: Yosipovitch, G., et al.
Publicado: (2019)

Intractable Itch in Atopic Dermatitis: Causes and Treatments
por: Umehara, Yoshie, et al.
Publicado: (2021)

Efficacy and Safety of Crisaborole Ointment, 2%, for the Treatment of Mild-to-Moderate Atopic Dermatitis Across Racial and Ethnic Groups
por: Callender, Valerie D., et al.
Publicado: (2019)

Itching in Atopic Dermatitis: Patient- and Physician-reported Outcomes in the German Atopic Dermatitis Registry TREATgermany
por: WEISSHAAR, Elke, et al.
Publicado: (2023)

Brain Processing of Contagious Itch in Patients with Atopic Dermatitis
por: Schut, Christina, et al.
Publicado: (2017)

Current Clinical Options for the Management of Itch in Atopic Dermatitis
por: Lipman, Zoe M, et al.
Publicado: (2021)

Crisaborole Ointment, 2%, for Treatment of Patients with Mild-to-Moderate Atopic Dermatitis: Systematic Literature Review and Network Meta-Analysis
por: Fahrbach, Kyle, et al.
Publicado: (2020)

Breaking the Itch–Scratch Cycle: Topical Options for the Management of Chronic Cutaneous Itch in Atopic Dermatitis
por: Harrison, Ian P., et al.
Publicado: (2019)

Neural Oscillation Associated with Contagious Itch in Patients with Atopic Dermatitis
por: Lee, In-Seon, et al.
Publicado: (2021)

The Pathology of Type 2 Inflammation-Associated Itch in Atopic Dermatitis
por: Moniaga, Catharina Sagita, et al.
Publicado: (2021)

Correction to: Crisaborole Ointment, 2%, for Treatment of Patients with Mild-to-Moderate Atopic Dermatitis: Systematic Literature Review and Network Meta-Analysis
por: Fahrbach, Kyle, et al.
Publicado: (2020)

Efficacy and Safety Trends with Continuous, Long-Term Crisaborole Use in Patients Aged ≥ 2 Years with Mild-to-Moderate Atopic Dermatitis
por: Geng, Bob, et al.
Publicado: (2021)

Characteristics of Atopic Dermatitis Patients Treated with Crisaborole: Real-World Data from a Large Healthcare Provider Database in Israel
por: Weil, Clara, et al.
Publicado: (2022)

Correction to: Efficacy and Safety Trends with Continuous, Long-Term Crisaborole Use in Patients Aged ≥ 2 Years with Mild-to-Moderate Atopic Dermatitis
por: Geng, Bob, et al.
Publicado: (2021)

Matching-Adjusted Indirect Comparison of Crisaborole Ointment 2% vs. Topical Calcineurin Inhibitors in the Treatment of Patients with Mild-to-Moderate Atopic Dermatitis
por: Thom, Howard, et al.
Publicado: (2021)

Is Itch Intensity in Atopic Dermatitis Associated with Skin Colonization by Staphylococcus aureus?
por: Blicharz, Leszek, et al.
Publicado: (2020)

An Altered Skin and Gut Microbiota Are Involved in the Modulation of Itch in Atopic Dermatitis
por: Moniaga, Catharina Sagita, et al.
Publicado: (2022)

Letter to the Editor Regarding ‘Crisaborole Ointment, 2%, for Treatment of Patients with Mild-to-Moderate Atopic Dermatitis: Systematic Literature Review and Network Meta-Analysis’
por: Luger, Thomas, et al.
Publicado: (2021)

The Role of the Microbiome and Microbiome-Derived Metabolites in Atopic Dermatitis and Non-Histaminergic Itch
por: Li, Wei, et al.
Publicado: (2020)

Molecular and cellular mechanisms of itch and pain in atopic dermatitis and implications for novel therapeutics
por: Kwatra, Shawn G, et al.
Publicado: (2022)

IL‐20 promotes cutaneous inflammation and peripheral itch sensation in atopic dermatitis
por: Lu, Zhiping, et al.
Publicado: (2022)

Response to the Letter to the Editor Regarding “Crisaborole Ointment, 2%, for Treatment of Patients with Mild-to-Moderate Atopic Dermatitis: Systemic Literature Review and Network Meta-Analysis”
por: Fahrbach, Kyle, et al.
Publicado: (2021)

The relationship between atopic dermatitis and atopic itch in children and the psychosocial functioning of their mothers: A cross-sectional study
por: Kobusiewicz, Aleksandra K., et al.
Publicado: (2023)

CROSS-CULTURAL ADAPTATION AND VALIDATION OF THE ITCHING SEVERITY SCALE IN CHILDREN AND ADOLESCENTS WITH ATOPIC DERMATITIS
por: Bruscky, Dayanne Mota Veloso, et al.
Publicado: (2017)

Itch Relief in Atopic Dermatitis: Comparison of Narrowband Ultraviolet B Radiation and Cyclosporine Treatment
por: JAWOREK, Andrzej, et al.
Publicado: (2020)

Compound traditional Chinese medicine dermatitis ointment ameliorates inflammatory responses and dysregulation of itch-related molecules in atopic dermatitis
por: Zhang, Rongrong, et al.
Publicado: (2022)

Evaluation of Itch by Using NC/NgaTnd Mice: A Model of Human Atopic Dermatitis
por: Tanaka, Akane, et al.
Publicado: (2011)

Association of Exposure to Wildfire Air Pollution With Exacerbations of Atopic Dermatitis and Itch Among Older Adults
por: Fadadu, Raj P., et al.
Publicado: (2022)

Development, Psychometric Validation and Responder Definition of Worst Itch Scale in Children with Severe Atopic Dermatitis
por: Paller, Amy S., et al.
Publicado: (2022)

Itch in Allergic Contact Dermatitis
por: Lambert, Julien
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_u00oie6p5h21g9as9a1qsc47rf